Berenberg Bank Forecasts Strong Price Appreciation for Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals (LON:HIK) had its target price boosted by equities research analysts at Berenberg Bank from GBX 1,800 to GBX 2,300 in a report released on Wednesday, Marketbeat reports. The brokerage presently has a “buy” rating on the stock. Berenberg Bank’s price objective points to a potential upside of 86.72% from the stock’s previous close.

Several other research analysts have also issued reports on the company. JPMorgan Chase & Co. lowered their target price on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a research report on Friday, November 7th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 2,360 price target on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. Peel Hunt reaffirmed a “buy” rating and issued a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. Finally, Deutsche Bank Aktiengesellschaft decreased their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating for the company in a research report on Friday, January 9th. Five analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of GBX 2,326.

Hikma Pharmaceuticals Trading Down 1.4%

Shares of LON HIK opened at GBX 1,231.78 on Wednesday. The company has a debt-to-equity ratio of 63.59, a quick ratio of 1.27 and a current ratio of 1.82. Hikma Pharmaceuticals has a 52-week low of GBX 1,210 and a 52-week high of GBX 2,184. The firm has a 50 day moving average price of GBX 1,531.81 and a two-hundred day moving average price of GBX 1,626.86. The stock has a market cap of £2.73 billion, a P/E ratio of 7.38, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.